Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis  Stephen Hanauer, Remo Panaccione, Silvio Danese, Adam Cheifetz, Walter Reinisch, Peter D.R. Higgins, Deborah A. Woodworth, Haiying Zhang, Gary S. Friedman, Nervin Lawendy, Daniel Quirk, Chudy I. Nduaka, Chinyu Su  Clinical Gastroenterology and Hepatology  Volume 17, Issue 1, Pages 139-147 (January 2019) DOI: 10.1016/j.cgh.2018.07.009 Copyright © 2019 AGA Institute Terms and Conditions

Figure 1 Proportion of patients with (A) Mayo stool frequency subscore = 0, (B) Mayo stool frequency subscore ≤1, and (C) reduction from baseline Mayo stool frequency subscore of ≥1 point, over time. Data are full analysis set, observed case. Day 0 represents data reported within 5 days before the baseline visit, and day 1 reflects the first dose of medication. Proportion of patients with reduction from baseline Mayo stool frequency subscore of ≥1 point excludes patients with baseline Mayo stool frequency subscore = 0. BID, twice daily. *P < .05. **P < .01. ***P < .0001 vs placebo. Clinical Gastroenterology and Hepatology 2019 17, 139-147DOI: (10.1016/j.cgh.2018.07.009) Copyright © 2019 AGA Institute Terms and Conditions

Figure 2 Proportions of patients with (A) Mayo rectal bleeding subscore = 0, (B) Mayo rectal bleeding subscore ≤1, and (C) reduction from baseline Mayo rectal bleeding subscore of ≥1 point, over time. Data are full analysis set, observed case. Day 0 represents data reported within 5 days before the baseline visit, and day 1 reflects the first dose of medication. Proportion of patients with reduction from baseline Mayo rectal bleeding subscore of ≥1 point excludes patients with baseline Mayo rectal bleeding subscore = 0. BID, twice daily. *P < .05. **P < .01. ***P < .0001 vs placebo. Clinical Gastroenterology and Hepatology 2019 17, 139-147DOI: (10.1016/j.cgh.2018.07.009) Copyright © 2019 AGA Institute Terms and Conditions

Figure 3 Proportion of patients with (A) reduction from baseline Mayo stool frequency subscore of ≥1 point over time, (B) Mayo rectal bleeding subscore = 0 over time, and (C) reduction from baseline Mayo rectal bleeding subscore of ≥1 point over time, by prior anti–tumor necrosis factor (TNF) failure (yes/no). Data are full analysis set, observed case. Day 0 represents data reported within 5 days before the baseline visit, and day 1 reflects the first dose of medication. Proportion of patients with reduction from baseline Mayo stool frequency subscore of ≥1 point excludes patients with baseline Mayo stool frequency subscore = 0. Proportion of patients with reduction from baseline Mayo rectal bleeding subscore of ≥1 point excludes patients with baseline Mayo rectal bleeding subscore = 0. BID, twice daily. Clinical Gastroenterology and Hepatology 2019 17, 139-147DOI: (10.1016/j.cgh.2018.07.009) Copyright © 2019 AGA Institute Terms and Conditions